Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.40 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.39 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | PLAT | P00750 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29891608 | 1.00 | HRH3 (0.44) | HRH3HRH4MKNK1MKNK2NISCH | |
| Hydrochloric Acid SCHEMBL20744274 | 0.98 | HRH3 (0.43) | HRH3HRH4MKNK1MKNK2NISCH | |
| SCHEMBL8271401 | 0.89 | CHEK1 (0.41) | HRH3MKNK1MKNK2NISCHGSK3B | |
| SCHEMBL3954850 | 0.89 | CHEK1 (0.41) | HRH3MKNK1MKNK2NISCHGSK3B | |
| SCHEMBL19116619 | 0.89 | CHEK1 (0.41) | HRH3MKNK1MKNK2NISCHGSK3B | |
| SCHEMBL29889443 | 0.89 | CHEK1 (0.41) | HRH3MKNK1MKNK2NISCHGSK3B | |
| Hydrochloric Acid SCHEMBL1024512 | 0.87 | CHEK1 (0.41) | HRH3MKNK1MKNK2NISCH | |
| SCHEMBL14250161 | 0.85 | — | — | |
| SCHEMBL30339210 | 0.85 | — | — | |
| SCHEMBL20995461 | 0.81 | CYP11B2 (0.44) | NISCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230010299-A1 | HETEROCYCLIC TRPML1 AGONISTS | LIBRA THERAPEUTICS, INC. | 2023-01-12 | — | — | US | claimed |
| EP-4058145-A1 | HETEROCYCLIC TRPML1 AGONISTS | Libra Therapeutics, Inc. (US) | 2022-09-21 | — | — | EP | claimed |
| WO-2021094974-A1 | HETEROCYCLIC TRPML1 AGONISTS | LIBRA THERAPEUTICS, INC. (US) | 2021-05-20 | — | — | WO | claimed |
| EP-3821947-A1 | HETEROCYCLIC TRPML1 AGONISTS | Libra Therapeutics, Inc. (US) | 2021-05-19 | — | — | EP | claimed |
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2025-11-25 | — | — | US | disclosed |
| US-11998539-B2 | Substituted aminoquinolones as DGKalpha inhibitors for immune activation | BAYER AKTIENGESELLSCHAFT (DE) | 2024-06-04 | — | — | US | disclosed |
| CN-112566637-B | GLP-1 receptor agonists and uses thereof | 辉瑞公司 | 2023-11-14 | — | — | CN | disclosed |
| US-20230201186-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-06-29 | — | — | US | disclosed |
| US-20230148194-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | BAYER AKTIENGESELLSCHAFT (DE) | 2023-05-11 | — | — | US | disclosed |
| US-20230010299-A1 | HETEROCYCLIC TRPML1 AGONISTS | LIBRA THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| EP-4065574-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | Bayer Aktiengesellschaft (DE) | 2022-10-05 | — | — | EP | disclosed |
| EP-4058145-A1 | HETEROCYCLIC TRPML1 AGONISTS | Libra Therapeutics, Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| US-9469615-B2 | Quinoxalines and AZA-quinoxalines as CRTH2 receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20130303517-A1 | QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS | MERCK SHARP & DOHME LLC | 2013-11-14 | — | — | US | disclosed |
| US-20130303517-A1 | QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS | MERCK SHARP & DOHME LLC | 2013-11-14 | — | — | US | disclosed |
| WO-2012087861-A1 | QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2012-06-28 | — | — | WO | disclosed |
| US-7491737-B2 | Heterarylpiperidine modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7491737-B2 | Heterarylpiperidine modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-5215967-A | AMINOACID DERIVATIVES INHIBITING RENIN | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1993-06-01 | — | — | US | disclosed |
| EP-0371390-A2 | Amino acid derivatives | MERCK PATENT GmbH (DE) | 1990-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303517-A1 | QUINOXALINES AND AZA-QUINOXALINES AS CRTH2 RECEPTOR MODULATORS | HRH2, NPY2R, CNKSR1 | HRH3 14/4885HRH4 10/4885MKNK1 1741/4885 |
| US-20230148194-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | DGKK, DGKG, DGKA | HRH3 411/4885HRH4 362/4885MKNK1 472/4885 |
| US-12478621-B2 | Substituted aminoquinolones as dgkalpha inhibitors for immune activation | DGKK, DGKG, DGKA | HRH3 411/4885HRH4 362/4885MKNK1 472/4885 |
| US-11998539-B2 | Substituted aminoquinolones as DGKalpha inhibitors for immune activation | DGKK, DGKG, DGKA | HRH3 411/4885HRH4 362/4885MKNK1 472/4885 |
| US-20230010299-A1 | HETEROCYCLIC TRPML1 AGONISTS | TRPM7, TRPM2, TRPM5 | HRH3 1414/4885HRH4 781/4885MKNK1 663/4885 |
| US-20230201186-A1 | SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION | DGKK, DGKG, DGKA | HRH3 411/4885HRH4 362/4885MKNK1 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.